Vivos Therapeutics
VVOS
22 hedge funds and large institutions have $243K invested in Vivos Therapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
8% less funds holding
Funds holding: 24 → 22 (-2)
13.59% less ownership
Funds ownership: 17.41% → 3.82% (-14%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
96% less capital inflows, than outflows
Capital inflows: $64.4K | Capital outflows: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHT Wealth Management
Chicago,
Illinois
|
+$28K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$22K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$6.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$1.32M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$167K |
| 3 |
XTX Topco
George Town,
Cayman Islands
|
-$29.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.26K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
-$5.8K |
VVOS Hedge Fund Activity: Q2 2026 in Review
22 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2026, worth a combined $243K — down 89% from $2.15M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VVOS and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was IHT Wealth Management, adding an estimated $28K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.32M sold.
- 22 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2026, down from 24 in Q1 2026.
- Funds reported $243K of Vivos Therapeutics stock for Q2 2026, down 89% quarter-over-quarter.
- 2 funds opened new Vivos Therapeutics positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest Vivos Therapeutics buyer in Q2 2026 was IHT Wealth Management, an estimated $28K added.
- The largest Vivos Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $1.32M sold.
Based on aggregated 13F filings for Q2 2026.